Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST trial in refractory non-convulsive status epilepticus
2021-003392-34Phase 3Active
- Sponsor
- University Hospital Odense
- Start
- Aug 2021
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of propofol, midazolam, brivaracetam, levetiracetam, fosphenytoin and 3 more in status epilepticus (SE) (2 arms), sponsored by University Hospital Odense. Primary endpoint: Treatment failure at 24 hours. Started Aug 2021; status: active.
02
Drugs
propofolmidazolambrivaracetamlevetiracetamfosphenytoin
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on 2021-003392-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003392-34.